Significant inhibition of corneal scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4833-4841

  Mohan, Rajiv R ^a,b,c   Tandon, Ashish ^a,b   Sharma, Ajay ^a,b   Cowden, John W ^b   Tovey, Jonathan C K ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD11B ANTIGEN; COLLAGEN FIBRIL; DECORIN; F ACTIN; FIBRONECTIN; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; CYTOTOXICITY; DECORIN GENE; FEMALE; GENE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; NICK END LABELING; NONHUMAN; OCULAR FIBROSIS; PRIORITY JOURNAL; RABBIT; SLIT LAMP; SLOT BLOT HYBRIDIZATION; STEREOMICROSCOPY; THERAPY EFFECT; TRANSMISSION ELECTRON MICROSCOPY; VIRAL GENE THERAPY; ADENO ASSOCIATED VIRUS; ANIMAL; APOPTOSIS; COMPARATIVE STUDY; CORNEA OPACITY; DISEASE COURSE; DISEASE MODEL; GENE THERAPY; METHODOLOGY; PATHOLOGY; PLASMID; SCANNING TRANSMISSION ELECTRON MICROSCOPY; SCAR; TOPICAL DRUG ADMINISTRATION; ULTRASTRUCTURE;

ADMINISTRATION, TOPICAL; ANIMALS; APOPTOSIS; CICATRIX; CORNEA; CORNEAL OPACITY; DECORIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE THERAPY; IMMUNOBLOTTING; IN SITU NICK-END LABELING; MICROSCOPY, ELECTRON, SCANNING TRANSMISSION; PLASMIDS; RABBITS;

EID: 80052359159     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7357     Document Type: Article

References (48)

1. Foster A, Resnikoff S. The impact of Vision 2020 on global blindness. Eye. 2005;19:1133-1135.
2. Congdon N, O'Colmain B, Klaver CC, et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
3. Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull. 2010;8:198-210.
4. Hassell JR, Birk DE. The molecular basis of corneal transparency. Exp Eye Res. 2010;91:326-335.
5. Wilson SE, Mohan RR, Mohan RR, Ambrósio R Jr, Hong J, Lee J. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res. 2001;20:625-637.
6. Seiler T, McDonnell PJ. Excimer laser photorefractive keratectomy. Surv Ophthalmol. 1995;40:89-118.
7. Netto MV, Mohan RR, Ambrósio R Jr, Hutcheon AE, Zieske JD, Wilson SE. Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea. 2005;24:509-522.
8. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE. Gene therapy in the cornea. Prog Retin Eye Res. 2005;24:537-559.
9. Sharma A, Ghosh A, Siddapa C, Mohan RR. Ocular Surface: Gene Therapy. In: Besharse J, Dana R, Dartt DA, eds. Encyclopedia of the Eye. Elsevier; 2010:185-194.
10. Mohan RR, Schultz GS, Hong JW, Mohan RR, Wilson SE. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res. 2003;76:373-383.
11. Sharma A, Ghosh A, Hansen ET, Newman JM, Mohan RR. Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts. Brain Res Bull. 2010;81:273-278.
12. Sharma A, Tovey JC, Ghosh A, Mohan RR. AAV serotype influences gene transfer in corneal stroma in vivo. Exp Eye Res. 2010;91:440-448.
13. Buss DG, Giuliano E, Sharma A, Mohan RR. Gene delivery in the equine cornea: a novel therapeutic strategy. Vet Ophthalmol. 2010;13:301-316.
14. Behrens A, McDonnell PJ. Gene therapy for the prevention of corneal haze after photorefractive/phototherapeutic keratectomy excimer laser surgery. Adv Exp Med Biol. 2002;506:1315-1321.
15. Behrens A, Gordon EM, Li L, et al. Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci. 2002;43:968-977.
16. Liu J, Saghizadeh M, Tuli SS, et al. Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapy. Mol Vis. 2008;14:2087-2096.
17. Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM. Novel AAV serotypes for improved ocular gene transfer. J Gene Med. 2008;10:375-382.
18. Mohan RR, Sharma A, Cebulko TC, Tandon A. Vector delivery technique affects gene transfer in the cornea in vivo. Mol Vis. 2010;16:2494-2501.
19. Mohan RR, Sinha S, Tandon A, Gupta R, Tovey JCK, Sharma A. Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea. PloS One. 2011;6:e18771.
20. Tandon A, Tovey JC, Sharma A, Gupta R, Mohan RR. Role of transforming growth factor beta in corneal function, biology and pathology. Curr Mol Med. 2010;10:565-578.
21. Jester JV, Petroll WM, Cavanagh HD. Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Prog Retin Eye Res. 1999;18:311-356.
22. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 1990;19:346:281-284.
23. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992;360:361-364.
24. Mohan RR, Tovey JC, Gupta R, Sharma A, Tandon A. Decorin biology, expression, function and therapy in the cornea. Curr Mol Med. 2011;11:110-128.
25. Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol. 1997;54:1205-1216.
26. Shimizukawa M, Ebina M, Narumi K, Kikuchi T, Munakata H, Nukiwa T. Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am J Physiol Lung Cell Mol Physiol. 2003;284:L526-L532.
27. Zhao J, Sime PJ, Bringas P Jr, Gauldie J, Warburton D. Adenovirusmediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol. 1999;277:L412-L422.
28. Kolb M, Margetts PJ, Galt T, et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med. 2001;163:770-777.
29. Zhang Z, Wu F, Zheng F, Li H. Adenovirus-mediated decorin gene transfection has therapeutic effects in a streptozocin-induced diabetic rat model. Nephron Exp Nephrol. 2010;116:e11-e21.
30. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther. 2009;20:1190-1200.
31. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med. 1996;2:418-423.
32. Margetts PJ, Gyorffy S, Kolb M, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol. 2002;13:721-728.
33. Mohan RR, Gupta R, Mehan MK, Cowden JW, Sinha S. Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Res. 2010;91: 238-245.
34. Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR. Trichostatin A inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci. 2009;50:2695-2701.
35. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods. 2002;28:158-167.
36. Barton RW, Rothlein R, Ksiazek J, Kennedy C. The effect of anti-intercellular adhesion molecule-1 on phorbol-ester-induced rabbit lung inflammation. J Immunol. 1989;143:1278-1282.
37. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A. 1998;95:10134-10139.
38. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem. 2008;283:21305-21309.
39. Ferdous Z, Wei VM, Iozzo R, Hook M, Grande-Allen KJ. Decorintransforming growth factor-interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem. 2007;7:282:35887-35898.
40. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. 2010;29:248-253.
41. Rada JA, Cornuet PK, Hassell JR. Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. Exp Eye Res. 1993;56:635-648.
42. Funderburgh JL, Hevelone ND, Roth MR. et al. Decorin and biglycan of normal and pathologic human corneas. Invest Ophthalmol Vis Sci. 1998;39:1957-1964.
43. Chakravarti S. Functions of lumican and fibromodulin: lessons from knockout mice. Glycoconj J. 2002;19:287-293.
44. Kao WW, Liu CY. Roles of lumican and keratocan on corneal transparency. Glycoconj J. 2002;19:275-285.
45. Carlson EC, Liu CY, Chikama T, et al. Keratocan, a cornea-specific keratan sulfate proteoglycan, is regulated by lumican. J Biol Chem. 2005;280:25541-25547.
46. Kays WT, Piatigorsky J. Aldehyde dehydrogenase class 3 expression: identification of a cornea-preferred gene promoter in transgenic mice. Proc Natl Acad Sci U S A. 1997;94:13594-13599.
47. Liu C, Arar H, Kao C, Kao WW. Identification of a 3.2 kb 5'-flanking region of the murine keratocan gene that directs beta-galactosidase expression in the adult corneal stroma of transgenic mice. Gene. 2000;250:85-96.
48. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 1997;136:729-743.